<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>NCT00942578 – A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer</title>
<link rel="stylesheet" href="../assets/styles.css"/>
</head><body><div class="container">
  <a href="../index.html">← Back to index</a>
  <h1>NCT00942578</h1>

  <div class="card">
    <div><strong>Title:</strong> A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer</div>
    <div class="meta"><strong>Year:</strong>  &nbsp; <strong>Authors:</strong> —</div>
    <div class="meta"><a href="https://clinicaltrials.gov/study/NCT00942578" target="_blank" rel="noopener">Registry page</a></div>
  </div>

  <div class="card">
    <h3>Study Documents</h3>
    <ul class="list">
      <li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/78/NCT00942578/Prot_SAP_ICF_000.pdf" target="_blank" rel="noopener">Study Protocol, Statistical Analysis Plan, and Informed Consent Form</a></li>
    </ul>
  </div>

  <div class="card">
    <h3>Preview</h3>
    <iframe class="pdf-iframe" src="https://mozilla.github.io/pdf.js/web/viewer.html?file=https://cdn.clinicaltrials.gov/large-docs/78/NCT00942578/Prot_SAP_ICF_000.pdf"></iframe>
  </div>
</div></body></html>
